Moderna's Flu Vaccine Application Set for FDA AdCom Review
Moderna (MRNA) will face a review by the FDA’s Vaccines and Related Biological Products Advisory Committee next month regarding its flu vaccine, mRNA-1010. The decision could impact investor sentiment around Moderna's expansion into seasonal vaccines.
Tickers: $MRNA
Topics: flu vaccine mRNA technology vaccines